# psoriasis - gpt-5.6-luna

- Benchmark system: raw
- Repeat: 5
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 3907
- Completion tokens: 5351
- Reasoning tokens: 
- Total tokens: 9258
- API requests reported: 
- Elapsed seconds: 99.713
- Final benchmark system: raw; file rank 3/5; original repeat 5; model vendor: OpenAI

---
## 1. Overall biological interpretation

The lesional skin profile shows a strongly activated psoriatic tissue state characterized by coordinated induction of:

1. **IL-36/IL-20-family inflammatory signaling**, including **IL36A, IL36G, IL19, IL20, IL26, IL36RN, TNIP3, IRAK2, and ZC3H12A**.
2. **Keratinocyte stress, hyperproliferation, and altered differentiation**, including **KRT6A, SPRR2A–G, LCE3A/LCE3D, SERPINB3/B4, S100A7/S100A7A, GJB2/GJB6, and RRM2/CCNE1**.
3. **Antimicrobial and innate defense activation**, especially **DEFB4A, DEFB4B, DEFB103A/B, PI3, S100A7, and S100A8/A12**.
4. **Myeloid/neutrophil-associated inflammatory recruitment**, supported by **S100A8, S100A12, TCN1, PLBD1, CXCR2, GPR15LG, and CXCL13**.
5. **Tissue remodeling and altered epithelial–immune communication**, including **WNT5A, HPSE, PLA2G4D/E, CD274, GJB2/GJB6, and ADGRF1**.

Most reported genes have very large effect sizes and extremely low FDR values. However, the magnitude of several changes—particularly **IL36A, DEFB4A/B, PI3, S100A7A, and S100A8/A12**—may reflect both true disease activation and differences in epidermal thickness, inflammatory-cell abundance, or relative cell composition between lesional and normal skin. The results strongly establish a lesional psoriasis-associated transcriptional state, but they do not by themselves establish causality or identify the cellular source of every transcript.

---

## 2. Core biological programs

### Program 1: IL-36/IL-20-family inflammatory epithelial signaling

**Direction:** Upregulated

**Major supporting genes:**  
**IL36A** (+11.37), **IL36G** (+5.68), **IL19** (+7.58), **IL20** (+5.67), **IL26** (+4.36), **IL36RN** (+3.01), **TNIP3** (+7.28), **IRAK2** (+2.08), **ZC3H12A** (+3.85)

**Appropriate pathway terminology:**

- GO: **cytokine-mediated signaling pathway**
- Reactome: **Cytokine signaling in immune system**
- Hallmark: **Inflammatory Response**
- More specific disease-relevant interpretation: **IL-36/IL-20-family cytokine signaling**

**Interpretation:**  
The simultaneous elevation of multiple IL-36 and IL-20-family ligands is more informative than any single cytokine. **IL36A and IL36G** are particularly strong epithelial inflammatory signals, while **IL19 and IL20** are consistent with cytokine communication between keratinocytes and immune cells. Upregulation of **IL36RN**, an endogenous IL-36 receptor antagonist, suggests activation of a compensatory negative-feedback response rather than simple unrestrained pathway activation. **TNIP3, IRAK2, and ZC3H12A** further support active innate inflammatory signaling and feedback regulation.

This pattern is biologically consistent with established psoriasis-associated inflammatory circuitry, although the current table does not contain receptor or downstream pathway activity measurements sufficient to prove pathway flux.

**Evidence strength:** Strong for an inflammatory cytokine-associated state.

- **Direct dataset evidence:** Multiple coordinated cytokine genes with very large positive log2FC and FDR <10⁻⁷⁸.
- **Pathway evidence:** The genes are members or regulators of cytokine and innate immune signaling.
- **Disease-association evidence:** IL-36 and IL-20-family signaling is well established in psoriatic skin biology.
- **Limitation:** Transcript abundance does not demonstrate cytokine protein production, receptor activation, or causal importance. IL36RN induction also indicates pathway counter-regulation.

---

### Program 2: Epidermal hyperproliferation, keratinocyte stress, and abnormal differentiation

**Direction:** Upregulated

**Major supporting genes:**  
**KRT6A**, **SPRR2A/B/D/E/F/G**, **LCE3A/LCE3D**, **SERPINB3**, **SERPINB4**, **SERPINB11**, **S100A7/S100A7A**, **GJB2/GJB6**, **RRM2**, **CCNE1**, **SLC6A14**

**Appropriate pathway terminology:**

- GO: **keratinization**, **epidermis development**, **epidermal cell differentiation**
- GO: **cell cycle**
- Hallmark: **E2F Targets** or **G2M Checkpoint** for the proliferative component
- Reactome: **Cornification**

**Interpretation:**  
The broad induction of small proline-rich proteins, late cornified envelope genes, keratins, serpin family members, and gap-junction genes indicates a major epidermal remodeling program. **KRT6A** is consistent with activated/stressed keratinocytes, while the coordinated **SPRR** and **LCE** induction indicates altered cornification and barrier-associated differentiation. **RRM2 and CCNE1** support increased proliferative activity, although proliferation cannot be inferred from these two genes alone without additional cell-cycle markers.

This is a tissue-level signature of the thickened, activated psoriatic epidermis. It is likely to be one of the most robust interpretations of the dataset because it is represented by many functionally related genes rather than a single marker.

**Evidence strength:** Strong for altered epidermal state; moderate for increased proliferation specifically.

- **Direct dataset evidence:** Numerous concordant epidermal structural and differentiation genes are strongly upregulated.
- **Ontology evidence:** The genes map to keratinization, cornification, epithelial differentiation, and cell-cycle processes.
- **Tissue evidence:** The pattern is compatible with lesional epidermal expansion and keratinocyte activation.
- **Limitation:** Increased transcript abundance can reflect more epidermal cells in lesions rather than transcriptional induction within individual keratinocytes.

---

### Program 3: Antimicrobial peptide and epithelial innate defense response

**Direction:** Upregulated

**Major supporting genes:**  
**DEFB4A**, **DEFB4B** (+11.03 to +11.18), **DEFB103A/B**, **PI3**, **S100A7**, **S100A7A**, **S100A8/A12**, **GPR15LG**

**Appropriate pathway terminology:**

- GO: **antimicrobial humoral response**
- GO: **defense response to bacterium**
- Reactome: **Antimicrobial peptides**
- Hallmark: **Inflammatory Response**

**Interpretation:**  
The coordinated elevation of several β-defensins, **PI3**, and S100-family inflammatory/antimicrobial genes indicates a strong epithelial innate-defense program. The magnitude of **DEFB4A/B** and **PI3** induction is particularly notable. This response may contribute to altered host–microbe interactions in lesional skin and is also a known downstream feature of inflammatory cytokine signaling, including IL-17/IL-36-related epithelial activation.

The data support the existence of an antimicrobial transcriptional state, but they do not establish whether microbial burden, microbial composition, or direct antimicrobial activity is altered.

**Evidence strength:** Strong for an antimicrobial/innate epithelial response; insufficient for claims about specific microbes or functional antimicrobial efficacy.

- **Direct dataset evidence:** Multiple antimicrobial and epithelial defense genes are among the most significantly induced.
- **Pathway evidence:** These genes are canonical antimicrobial-peptide and epithelial-defense components.
- **Disease-association evidence:** Similar antimicrobial peptide induction is characteristic of psoriatic lesions.
- **Limitation:** The table contains no microbiome, protein, or functional killing assay data. Some S100 genes may also reflect infiltrating myeloid cells.

---

### Program 4: Myeloid/neutrophil-associated inflammation and leukocyte recruitment

**Direction:** Upregulated

**Major supporting genes:**  
**S100A8**, **S100A12**, **TCN1**, **PLBD1**, **CXCR2**, **GPR15LG**, **CXCL13**, **ADAP2**, **TRIM15**

**Appropriate pathway terminology:**

- GO: **neutrophil chemotaxis**
- GO: **leukocyte migration**
- GO: **myeloid leukocyte activation**
- Reactome: **Chemokine receptors bind chemokines**
- Hallmark: **Inflammatory Response**

**Interpretation:**  
The induction of **S100A8/A12**, **TCN1**, and **PLBD1** is consistent with increased myeloid and/or neutrophil representation in lesional skin. **CXCR2** supports a neutrophil-recruitment axis, whereas **GPR15LG** and **CXCL13** indicate broader immune-cell communication. This program is likely relevant to the inflammatory infiltrate and may help explain the tissue-level elevation of antimicrobial and inflammatory transcripts.

The interpretation is particularly vulnerable to cell-composition confounding. In bulk tissue, increased expression may result from more neutrophils or inflammatory myeloid cells rather than activation of resident keratinocytes.

**Evidence strength:** Strong for a myeloid-associated tissue signal; moderate for a specific neutrophil-recruitment mechanism.

- **Direct dataset evidence:** Multiple genes associated with neutrophils, myeloid cells, and leukocyte trafficking are induced.
- **Pathway evidence:** The genes converge on chemotaxis and innate immune-cell activation.
- **Tissue evidence:** Compatible with inflammatory-cell accumulation in psoriatic plaques.
- **Limitation:** Bulk expression cannot resolve whether these genes originate from neutrophils, monocytes, keratinocytes, or mixed populations. **CXCL13** is not specific to one immune-cell type.

---

### Program 5: Tissue remodeling and epithelial–immune interface

**Direction:** Upregulated

**Major supporting genes:**  
**WNT5A**, **HPSE**, **PLA2G4D**, **PLA2G4E**, **GJB2**, **GJB6**, **CD274**, **ADGRF1**, **TMPRSS11D**

**Appropriate pathway terminology:**

- GO: **extracellular matrix organization**
- GO: **cell–cell junction organization**
- GO: **epithelial cell–cell adhesion**
- Reactome: **Cell junction organization**
- Broadly: **epithelial–immune signaling and tissue remodeling**

**Interpretation:**  
This gene set suggests remodeling of epithelial communication, lipid/inflammatory mediator metabolism, junctional biology, and immune interaction. **PLA2G4D/E** may reflect altered epidermal lipid mediator pathways, while **HPSE** and **WNT5A** are compatible with extracellular remodeling and altered tissue signaling. **CD274** indicates increased expression of an immune-regulatory checkpoint ligand, but its cellular source and functional consequence are not defined.

This is a more heterogeneous program than the epidermal or antimicrobial programs and should be considered a secondary interpretation unless supported by formal enrichment or protein-level data.

**Evidence strength:** Moderate for tissue remodeling and altered epithelial–immune communication.

- **Direct dataset evidence:** Several structurally or functionally related genes are upregulated.
- **Pathway evidence:** The genes map to junctional, extracellular, lipid mediator, and signaling processes.
- **Disease/literature evidence:** These processes are relevant to inflammatory skin disease.
- **Limitation:** The genes do not define one compact pathway, and transcript-level changes do not establish altered barrier permeability, lipid mediator production, or immune checkpoint function.

---

## 3. Key genes and interaction modules

The following candidates are prioritized as modules or representative genes rather than as isolated disease drivers.

| Candidate | Dataset direction | Role and relationship |
|---|---:|---|
| **IL36A–IL36G–IL36RN module** | All upregulated; IL36A +11.37, IL36G +5.68, IL36RN +3.01 | Central IL-36 inflammatory module. **IL36A/G and IL36RN are pathway co-members and regulatory counterparts**; IL36RN is an antagonist of IL-36 receptor signaling. This is a **regulatory/pathway relationship**, not evidence of direct physical interaction among the transcripts. |
| **IL19–IL20–IL26 module** | Upregulated | Represents cytokine-mediated epithelial–immune communication. These genes are **pathway co-members and potentially indirect signaling partners**. The dataset does not establish which cells produce them or whether their proteins are active. |
| **DEFB4A–DEFB4B–DEFB103A/B module** | Strongly upregulated; DEFB4A/B approximately +11 | Coordinated antimicrobial peptide response. These genes are **functional co-members of antimicrobial defense**, not necessarily direct protein interactors. Their induction may be downstream of shared inflammatory signaling. |
| **S100A7/S100A7A–S100A8–S100A12 module** | Upregulated; S100A7A +9.83, S100A8 +7.73, S100A12 +8.33 | Integrates epithelial stress/antimicrobial activity with myeloid inflammation. Relationships are primarily **co-expression and indirect inflammatory network relationships**. S100A8/A12 may be myeloid-derived, whereas S100A7/A7A are commonly epithelial-associated; single-cell localization is needed. |
| **SPRR/LCE/SERPIN epidermal differentiation module** | Broadly upregulated | Indicates abnormal cornification, barrier remodeling, and keratinocyte stress. These genes are **pathway co-members and co-expressed structural modules**, not a demonstrated direct interaction complex. |
| **KRT6A–GJB2/GJB6 module** | Upregulated | Consistent with activated keratinocytes and altered epithelial junctional communication. The relationship is **cell-state co-expression and pathway co-membership**, not proven direct interaction. |
| **RRM2–CCNE1 proliferative module** | Upregulated; RRM2 +2.72, CCNE1 +2.56 | Supports increased cell-cycle activity in lesional epidermis. These genes are **regulatory/pathway co-members** in proliferation; the dataset does not show a direct physical interaction. |
| **CXCR2–S100A8/A12–TCN1/PLBD1 module** | Upregulated | Suggests neutrophil/myeloid accumulation and recruitment. The relationship is **indirect cellular/network association**. CXCR2 expression alone does not prove ligand-driven recruitment. |
| **CD274** | Upregulated, +3.44 | Candidate marker of immune-regulatory activation at the lesional interface. Its relationship to the inflammatory modules is **indirect and regulatory/associational**. It should not be interpreted as evidence that PD-1/PD-L1 signaling is functionally dominant in psoriasis. |
| **WNT5A–HPSE–PLA2G4D/E module** | Upregulated | Exploratory tissue-remodeling and lipid/inflammatory mediator module. Current evidence supports **pathway co-membership or indirect relationship**, but not a unified mechanistic module with confidence. |

---

## 4. Validation priorities

### 1. IL-36-centered epithelial inflammation  
**Classification:** Mechanistic hypothesis

**Why prioritize:**  
The IL-36 axis is supported by coordinated induction of **IL36A, IL36G, IL36RN, IL19, and IL20**, with exceptionally strong statistical significance. This is more compelling than a single-gene association.

**External evidence:**  
Published psoriasis research supports IL-36 signaling as an important inflammatory pathway, particularly in keratinocyte-mediated amplification. However, the current data also show induction of **IL36RN**, indicating endogenous negative feedback. Evidence therefore supports pathway involvement but not necessarily that IL-36 is the dominant causal driver in every lesion.

**Next step:**  
Measure IL-36 cytokine proteins and receptor-pathway activation in lesional keratinocytes; use ex vivo skin or primary keratinocyte perturbation with IL-36 blockade or stimulation.

**Conclusion status:** **Supported hypothesis**, not established causality.

---

### 2. Antimicrobial peptide and barrier remodeling signature  
**Classification:** Biomarker

**Why prioritize:**  
The combined **DEFB4A/B, DEFB103A/B, PI3, S100A7/A7A, SPRR, and LCE** signal is highly reproducible in concept and may distinguish lesional from nonlesional or normal skin.

**External evidence:**  
Antimicrobial peptide induction and epidermal differentiation abnormalities are well recognized features of psoriatic lesions. However, transcript abundance may be influenced by epidermal thickness and inflammatory composition.

**Next step:**  
Validate by qPCR, immunohistochemistry, or targeted proteomics in an independent cohort, including lesional, nonlesional, and normal skin. Assess diagnostic performance and correlation with lesion severity.

**Conclusion status:** **Supported hypothesis** as a tissue biomarker; clinical utility remains unestablished.

---

### 3. Neutrophil/myeloid composition versus true activation  
**Classification:** Confounding or composition check

**Why prioritize:**  
**S100A8/A12, TCN1, PLBD1, CXCR2, and ADAP2** may reflect increased abundance of infiltrating myeloid cells rather than altered expression in resident skin cells. This distinction affects interpretation of both inflammatory mechanisms and biomarker specificity.

**External evidence:**  
Psoriatic lesions commonly contain inflammatory myeloid and neutrophil populations, but the source of each transcript cannot be inferred reliably from bulk data.

**Next step:**  
Perform single-cell or spatial transcriptomics, immunostaining for neutrophil and myeloid markers, and deconvolution using validated reference profiles. Compare expression per cell type rather than only bulk tissue abundance.

**Conclusion status:** **Established concern**, with the biological attribution currently unresolved.

---

### 4. IL-36/epidermal differentiation interaction network  
**Classification:** Interaction / network hypothesis

**Why prioritize:**  
The data show simultaneous activation of inflammatory cytokines and epidermal structural programs, suggesting that cytokine signaling may contribute to keratinocyte stress, antimicrobial peptide induction, and altered differentiation.

**External evidence:**  
There is substantial literature supporting cytokine-driven keratinocyte activation, but the current data cannot determine whether cytokine activation precedes epidermal remodeling or is a consequence of tissue injury and altered composition.

**Next step:**  
Use primary human keratinocytes or organotypic skin models with IL-36 stimulation or inhibition and quantify **DEFB4A/B, S100A7, KRT6A, SPRR genes, and LCE genes**. Perturbation combined with time-course analysis would help distinguish regulatory effects from shared downstream co-expression.

**Conclusion status:** **Supported hypothesis**, not a demonstrated direct gene–gene interaction.

---

### 5. CD274 and immune-regulatory remodeling  
**Classification:** Therapeutic target

**Why prioritize:**  
**CD274** is significantly upregulated and may indicate altered immune-regulatory signaling in lesions. It is potentially translationally relevant but should not be prioritized as a therapeutic target solely because a drug class exists.

**External evidence:**  
PD-L1 biology is context dependent. Immune checkpoint modulation can produce different outcomes across inflammatory diseases, and enhancement or blockade may not be beneficial in psoriasis. The current dataset lacks evidence of PD-1 expression, ligand engagement, or functional T-cell suppression.

**Next step:**  
Localize CD274 protein to keratinocytes, myeloid cells, or other cell types; measure PDCD1-positive immune populations and functional T-cell responses. Therapeutic interpretation should require disease-specific perturbation data, not transcript elevation alone.

**Conclusion status:** **Exploratory hypothesis**; insufficient evidence to nominate CD274 as an effective psoriasis target.

---

## 5. Evidence grounding and interpretation of relationships

- **Direct statistical evidence:** Nearly all highlighted genes are significantly upregulated with very small FDR values. This establishes differential expression, not mechanism.
- **Pathway/ontology evidence:** The programs are inferred from known gene functions and pathway membership. Formal pathway enrichment was not supplied, so pathway labels should be regarded as biologically informed annotation rather than independently calculated enrichment results.
- **Disease-association evidence:** The IL-36 axis, keratinocyte activation, antimicrobial peptides, and myeloid inflammation are consistent with established psoriasis biology.
- **Protein/regulatory evidence:** Some relationships, such as IL36RN antagonism of IL-36 signaling, are supported by known molecular biology. Most other proposed relationships are pathway co-membership, co-expression, or indirect cellular association.
- **Tissue-specific evidence:** The strong epidermal differentiation signature is compatible with lesional skin architecture. Nevertheless, bulk tissue composition may produce or amplify these signals.
- **Genetic or clinical evidence:** No genotype, treatment-response, severity, or outcome data were provided. Therefore, causal genetic support and clinical predictive value cannot be assessed.
- **Therapeutic evidence:** No therapeutic efficacy can be inferred from these expression results. Drug availability is not evidence that a gene is an effective target in psoriasis.

The strongest conclusions are supported by multiple genes within coherent programs. They are not fully independent of one another: for example, IL-36, antimicrobial peptides, and keratinocyte differentiation may all be downstream consequences of overlapping inflammatory signaling. Thus, apparent convergence does not necessarily represent three independent causal mechanisms.

---

## 6. Major limitations and alternative explanations

1. **Cellular composition and epidermal expansion**  
   Lesional skin contains more activated epidermis and inflammatory cells than normal skin. This can explain part of the elevation of keratinocyte, neutrophil, and myeloid transcripts.  
   **Investigation:** single-cell/spatial profiling, histologic quantification, immunostaining, and cell-type deconvolution.

2. **Disease severity and lesion state**  
   Very large fold changes may reflect highly inflamed plaques, disease duration, or a particular clinical subtype.  
   **Investigation:** correlate expression with PASI, lesion age, and clinical phenotype across independent patients.

3. **Treatment exposure**  
   Topical or systemic therapies may suppress or reshape inflammatory programs. Treatment information is not provided.  
   **Investigation:** analyze treatment-naïve samples or adjust for treatment exposure and sampling interval.

4. **Bulk-transcriptomic and technical effects**  
   Low baseline expression in normal skin can yield very large log2FC values. Batch, platform, RNA quality, and sample handling can also affect results.  
   **Investigation:** inspect normalized expression distributions, replicate concordance, batch covariates, and validation by orthogonal assays.

5. **Association versus causation**  
   Differential expression does not establish that any highlighted gene initiates psoriasis or that inhibiting it will improve disease. Several genes may be downstream markers of a shared inflammatory environment.  
   **Investigation:** time-course studies, ex vivo perturbation, genetic evidence, and controlled functional experiments are required.

### Overall conclusion

The dataset provides strong evidence for a coordinated psoriatic lesional state involving **IL-36/IL-20-family inflammation, epidermal remodeling and hyperproliferation, antimicrobial defense, and myeloid/neutrophil-associated inflammation**. The most reliable immediate uses are disease-state characterization, tissue biomarker development, and prioritization of mechanistic experiments. Attribution of signals to specific cell types and causal ranking of pathways require spatial or single-cell localization and functional perturbation.
